Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.

Dumas EK, Garman L, Cuthbertson H, Charlton S, Hallis B, Engler RJM, Choudhari S, Picking WD, James JA, Farris AD.

Vaccine. 2017 Jun 8;35(26):3416-3422. doi: 10.1016/j.vaccine.2017.05.006. Epub 2017 May 11.

PMID:
28504191
2.

Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease.

Balderas MA, Nguyen CT, Terwilliger A, Keitel WA, Iniguez A, Torres R, Palacios F, Goulding CW, Maresso AW.

Infect Immun. 2016 Nov 18;84(12):3408-3422. Print 2016 Dec.

3.

A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines.

Laws TR, Kuchuloria T, Chitadze N, Little SF, Webster WM, Debes AK, Saginadze S, Tsertsvadze N, Chubinidze M, Rivard RG, Tsanava S, Dyson EH, Simpson AJ, Hepburn MJ, Trapaidze N.

PLoS One. 2016 Mar 23;11(3):e0148713. doi: 10.1371/journal.pone.0148713. eCollection 2016.

4.

Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.

Quinn CP, Sabourin CL, Schiffer JM, Niemuth NA, Semenova VA, Li H, Rudge TL, Brys AM, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Parker SD, Babcock J, Keitel W, Poland GA, Keyserling HL, El Sahly H, Jacobson RM, Marano N, Plikaytis BD, Wright JG.

Clin Vaccine Immunol. 2016 Apr 4;23(4):326-38. doi: 10.1128/CVI.00696-15. Print 2016 Apr.

5.

Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques.

Chen L, Schiffer JM, Dalton S, Sabourin CL, Niemuth NA, Plikaytis BD, Quinn CP.

Clin Vaccine Immunol. 2014 Nov;21(11):1512-20. doi: 10.1128/CVI.00469-14. Epub 2014 Sep 3.

6.

Genomic copy number variants: evidence for association with antibody response to anthrax vaccine adsorbed.

Falola MI, Wiener HW, Wineinger NE, Cutter GR, Kimberly RP, Edberg JC, Arnett DK, Kaslow RA, Tang J, Shrestha S.

PLoS One. 2013 May 31;8(5):e64813. doi: 10.1371/journal.pone.0064813. Print 2013.

7.

Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.

Ionin B, Hopkins RJ, Pleune B, Sivko GS, Reid FM, Clement KH, Rudge TL Jr, Stark GV, Innes A, Sari S, Guina T, Howard C, Smith J, Swoboda ML, Vert-Wong E, Johnson V, Nabors GS, Skiadopoulos MH.

Clin Vaccine Immunol. 2013 Jul;20(7):1016-26. doi: 10.1128/CVI.00099-13. Epub 2013 May 8.

8.

Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge.

Fay MP, Follmann DA, Lynn F, Schiffer JM, Stark GV, Kohberger R, Quinn CP, Nuzum EO.

Sci Transl Med. 2012 Sep 12;4(151):151ra126. doi: 10.1126/scitranslmed.3004073.

9.

Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.

Kyriacou DN, Dobrez D, Parada JP, Steinberg JM, Kahn A, Bennett CL, Schmitt BP.

Biosecur Bioterror. 2012 Sep;10(3):264-79. Epub 2012 Jul 30.

10.

Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax.

Lovchik JA, Drysdale M, Koehler TM, Hutt JA, Lyons CR.

Infect Immun. 2012 Jul;80(7):2414-25. doi: 10.1128/IAI.06340-11. Epub 2012 Apr 23.

11.

Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.

Bellanti JA, Lin FY, Chu C, Shiloach J, Leppla SH, Benavides GA, Karpas A, Moayeri M, Guo C, Robbins JB, Schneerson R.

Clin Vaccine Immunol. 2012 Feb;19(2):140-5. doi: 10.1128/CVI.05556-11. Epub 2011 Dec 21.

12.
13.

The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed.

Pajewski NM, Parker SD, Poland GA, Ovsyannikova IG, Song W, Zhang K, McKinney BA, Pankratz VS, Edberg JC, Kimberly RP, Jacobson RM, Tang J, Kaslow RA.

Genes Immun. 2011 Sep;12(6):457-65. doi: 10.1038/gene.2011.15. Epub 2011 Mar 3.

14.

Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Brown BK, Cox J, Gillis A, VanCott TC, Marovich M, Milazzo M, Antonille TS, Wieczorek L, McKee KT Jr, Metcalfe K, Mallory RM, Birx D, Polonis VR, Robb ML.

PLoS One. 2010 Nov 5;5(11):e13849. doi: 10.1371/journal.pone.0013849.

15.

Anthrax vaccination strategies.

Cybulski RJ Jr, Sanz P, O'Brien AD.

Mol Aspects Med. 2009 Dec;30(6):490-502. doi: 10.1016/j.mam.2009.08.006. Epub 2009 Sep 1. Review.

16.

Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Osorio M, Wu Y, Singh S, Merkel TJ, Bhattacharyya S, Blake MS, Kopecko DJ.

Infect Immun. 2009 Apr;77(4):1475-82. doi: 10.1128/IAI.00828-08. Epub 2009 Jan 29.

17.

Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors.

Liu TH, Oscherwitz J, Schnepp B, Jacobs J, Yu F, Cease KB, Johnson PR.

Mol Ther. 2009 Feb;17(2):373-9. doi: 10.1038/mt.2008.242. Epub 2008 Nov 11.

18.

Effect of CpG oligonucleotides on vaccine-induced B cell memory.

Tross D, Klinman DM.

J Immunol. 2008 Oct 15;181(8):5785-90.

19.

Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.

Cybulski RJ Jr, Sanz P, McDaniel D, Darnell S, Bull RL, O'Brien AD.

Vaccine. 2008 Sep 8;26(38):4927-39. doi: 10.1016/j.vaccine.2008.07.015. Epub 2008 Jul 25.

20.

Conference report on public health and clinical guidelines for anthrax.

Stern EJ, Uhde KB, Shadomy SV, Messonnier N.

Emerg Infect Dis. 2008 Apr;14(4). pii: 07-0969. doi: 10.3201/eid1404.070969.

Supplemental Content

Support Center